

## Viracta Therapeutics to Present at the Evercore ISI HealthCONx Conference

*San Diego, Nov. 27, 2019 /PRNewswire/* - Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, today announced that Ivor Royston, MD, President and Chief Executive Officer of Viracta, will present a company overview at the Evercore ISI HealthCONx Conference on Wednesday, December 4, 2019 at 2:45 pm ET in Boston, MA.

### **About Viracta Therapeutics, Inc.**

Viracta is a precision oncology company targeting virus-associated malignancies. The Company's proprietary lead molecule, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for Epstein-Barr virus positive lymphomas. Viracta is pursuing application of this *Kick and Kill* platform approach in other EBV associated malignancies, such as nasopharyngeal carcinoma, and other viral related cancers.

For additional information please visit [www.viracta.com](http://www.viracta.com).

### **Media Contact:**

Amy Conrad  
Juniper Point  
amy@juniper-point.com  
858-366-3243

### **Investor Contact:**

Sam Martin  
Argot Partners  
sam@argotpartners.com  
212-600-1902

---

<https://viracta.investorroom.com/2019-11-27-Viracta-Therapeutics-to-Present-at-the-Evercore-ISI-HealthCONx-Conference>